奧拉西坦聯(lián)合鼠神經(jīng)生長因子治療重型腦外傷的臨床觀察及其對血清神經(jīng)元特異性烯醇化酶的影響

朱美　任新海　陳新　王琪鴻　曾明泉　張何源　鐘文詩

【摘要】 目的：探討奧拉西坦注射液聯(lián)合鼠神經(jīng)生長因子治療急性重型顱腦損傷的臨床效果及其對血清神經(jīng)元特異性烯醇化酶（neuron-specific enolase NSE）的影響。方法：選擇福建中醫(yī)院大學(xué)附屬人民醫(yī)院收治的60例重型顱腦損傷患者，對照組30例給予常規(guī)方法治療14 d。治療組在對照組常規(guī)方法治療基礎(chǔ)上加用奧拉西坦注射液和鼠神經(jīng)生長因子治療14 d。觀察兩組治療前后格拉斯哥昏迷評分（GCS）、Glasgow（GOS）評分情況以及治療過程中NSE的變化情況。結(jié)果：治療組治療第7、14天GCS評分、GOS評分良好率較對照組好，治療第7天的NSE水平較低，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論：奧拉西坦注射液聯(lián)合神經(jīng)生長因子治療重型急性顱腦損傷具有較好的臨床效果，能夠改善預(yù)后情況，降低NSE水平，具有一定的臨床推廣應(yīng)用價(jià)值。

【關(guān)鍵詞】 注射用鼠神經(jīng)生長因子； 注射用奧拉西坦； 急性顱腦損傷； 神經(jīng)元特異性烯醇化酶； 格拉斯哥昏迷評分

doi：10.14033/j.cnki.cfmr.2017.30.001 文獻(xiàn)標(biāo)識碼 A 文章編號 1674-6805（2017）30-0001-03

The Clinical Observation of Oxiracetam with Mouse Nerve Growth Factor in the Treatment of Severe Craniocerebral Injury and Its Effect on Serum Neuronal Specific Enolase/ZHU Mei，REN Xin-hai，CHEN Xin，et al.//Chinese and Foreign Medical Research，2017，15（30）：1-3

【Abstract】 Objective：To investigate the clinical effect of Oxiracetam for injection combined with Mouse Nerve Growth Factor on acute severe craniocerebral injury and its effect on the serum neuron specific enolase（NSE）.Method：Sixty patients with severe craniocerebral injury in the Affiliated Peoples Hospital of Fujian University of Traditional Chinese Medicine were selected，and 30 patients in the control group were treated with normal treatment for 14 days.The treatment group based on conventional treatment were treated with the injection of Oxiracetam and Mouse Nerve Growth Factor for 14 days.The Glasgow Coma Scale（GCS），Glasgow（GOS） score were observed before and after treatment and the change of NSE in the course of treatment was observed in the two groups.Result：The scores of GCS at the seventh and fourteenth day of the treatment and the good rate of GOS in the treatment group were better than the control group，the NSE level at the 7th day of the treatment group was lower，the differences were statistically significant（P<0.05）.Conclusion：Oxiracetam for injection combined with Mouse Nerve Growth Factor in the treatment of severe craniocerebral injury has better clinical efficacy，can improve the prognosis，reduce the level of NSE，which has certain clinical application value.

【Key words】 Mouse Nerve Growth Factor for injection； Oxiracetam for injection； Acute craniocerebral injury； Neuron specific enolase； Glasgow coma scale

First-authors address：The Affiliated Peoples Hospital of Fujian University of Traditional Chinese Medicine，F(xiàn)uzhou 350004，China

隨著社會的不斷進(jìn)步，各種交通事故得到了有效控制，但是急性顱腦損傷仍然是神經(jīng)外科常見病，其中重型顱腦損傷的高致殘率、不低的致死率給家庭和社會帶來沉重負(fù)擔(dān)，仍然是醫(yī)療工作者及社會面對的一個(gè)共同難題，因此需要對其進(jìn)行積極地科學(xué)合理的治療，以達(dá)到減少并發(fā)癥、減輕后遺癥，促進(jìn)早日恢復(fù)的目的。而針對其病情及預(yù)后早期評估主要依賴于影像學(xué)資料及格拉斯哥昏迷評分（GCS）評價(jià)，缺乏其他客觀的實(shí)驗(yàn)室指標(biāo)，臨床工作者正在積極尋找其他能有效評估腦損傷嚴(yán)重度的指標(biāo)，其中血清神經(jīng)元特異性烯醇化酶（NSE）等指標(biāo)備受臨床關(guān)注[1]。……